Financhill
Sell
35

MLSS Quote, Financials, Valuation and Earnings

Last price:
$0.90
Seasonality move :
-5.1%
Day range:
$0.90 - $0.99
52-week range:
$0.54 - $1.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.13x
P/B ratio:
9.92x
Volume:
96.9K
Avg. volume:
101.4K
1-year change:
31.23%
Market cap:
$71.7M
Revenue:
$9.8M
EPS (TTM):
-$0.07

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
MLSS
Milestone Scientific
$2.7M -$0.01 17.38% -66.67% --
AIM
AIM ImmunoTech
$100K -$0.09 -23.08% -53.85% $2.75
EMBC
Embecta
$256.1M $0.44 -8.86% 17.5% $22.00
GOSS
Gossamer Bio
$7M -$0.17 -96.37% -1.78% $7.61
INGN
Inogen
$73.9M -$0.49 1.98% -59.68% $10.00
LUCD
Lucid Diagnostics
$1.4M -$0.15 36.96% -41.33% $3.50
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
MLSS
Milestone Scientific
$0.92 -- $71.7M -- $0.00 0% 8.13x
AIM
AIM ImmunoTech
$0.12 $2.75 $7.6M -- $0.00 0% 32.98x
EMBC
Embecta
$13.00 $22.00 $755.7M 13.00x $0.15 4.62% 0.68x
GOSS
Gossamer Bio
$1.30 $7.61 $294.6M -- $0.00 0% --
INGN
Inogen
$7.45 $10.00 $197.6M -- $0.00 0% 0.52x
LUCD
Lucid Diagnostics
$1.28 $3.50 $76M -- $0.00 0% 14.20x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
MLSS
Milestone Scientific
-- 2.706 -- 1.42x
AIM
AIM ImmunoTech
48.41% 1.568 17.25% 0.71x
EMBC
Embecta
199.15% 4.480 128.64% 1.44x
GOSS
Gossamer Bio
78.47% 0.197 88.26% 6.53x
INGN
Inogen
-- 4.168 -- 1.88x
LUCD
Lucid Diagnostics
61.68% -2.277 10.41% 1.02x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
MLSS
Milestone Scientific
$1.8M -$1.5M -61.33% -61.33% -58.44% -$973.9K
AIM
AIM ImmunoTech
$27K -$4.5M -219.06% -256.33% -9994.29% -$3.3M
EMBC
Embecta
$157.1M $39.1M 7.12% -- 10.39% -$6.8M
GOSS
Gossamer Bio
-- -$33.9M -- -- -308.03% -$32M
INGN
Inogen
$36.3M -$11.4M -19.02% -19.02% -14.22% -$6.2M
LUCD
Lucid Diagnostics
-$512K -$11.7M -229.99% -650.37% -1055.46% -$10.5M

Milestone Scientific vs. Competitors

  • Which has Higher Returns MLSS or AIM?

    AIM ImmunoTech has a net margin of -58.13% compared to Milestone Scientific's net margin of -10571.43%. Milestone Scientific's return on equity of -61.33% beat AIM ImmunoTech's return on equity of -256.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    MLSS
    Milestone Scientific
    73.05% -$0.02 $7.2M
    AIM
    AIM ImmunoTech
    77.14% -$0.06 $5.6M
  • What do Analysts Say About MLSS or AIM?

    Milestone Scientific has a consensus price target of --, signalling upside risk potential of 131%. On the other hand AIM ImmunoTech has an analysts' consensus of $2.75 which suggests that it could grow by 2191.67%. Given that AIM ImmunoTech has higher upside potential than Milestone Scientific, analysts believe AIM ImmunoTech is more attractive than Milestone Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    MLSS
    Milestone Scientific
    0 0 0
    AIM
    AIM ImmunoTech
    1 0 0
  • Is MLSS or AIM More Risky?

    Milestone Scientific has a beta of 1.409, which suggesting that the stock is 40.929% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.411, suggesting its less volatile than the S&P 500 by 58.887%.

  • Which is a Better Dividend Stock MLSS or AIM?

    Milestone Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Scientific pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MLSS or AIM?

    Milestone Scientific quarterly revenues are $2.5M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Milestone Scientific's net income of -$1.5M is higher than AIM ImmunoTech's net income of -$3.7M. Notably, Milestone Scientific's price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Scientific is 8.13x versus 32.98x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MLSS
    Milestone Scientific
    8.13x -- $2.5M -$1.5M
    AIM
    AIM ImmunoTech
    32.98x -- $35K -$3.7M
  • Which has Higher Returns MLSS or EMBC?

    Embecta has a net margin of -58.13% compared to Milestone Scientific's net margin of --. Milestone Scientific's return on equity of -61.33% beat Embecta's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MLSS
    Milestone Scientific
    73.05% -$0.02 $7.2M
    EMBC
    Embecta
    59.99% -- $775.4M
  • What do Analysts Say About MLSS or EMBC?

    Milestone Scientific has a consensus price target of --, signalling upside risk potential of 131%. On the other hand Embecta has an analysts' consensus of $22.00 which suggests that it could grow by 69.23%. Given that Milestone Scientific has higher upside potential than Embecta, analysts believe Milestone Scientific is more attractive than Embecta.

    Company Buy Ratings Hold Ratings Sell Ratings
    MLSS
    Milestone Scientific
    0 0 0
    EMBC
    Embecta
    1 2 0
  • Is MLSS or EMBC More Risky?

    Milestone Scientific has a beta of 1.409, which suggesting that the stock is 40.929% more volatile than S&P 500. In comparison Embecta has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock MLSS or EMBC?

    Milestone Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Embecta offers a yield of 4.62% to investors and pays a quarterly dividend of $0.15 per share. Milestone Scientific pays -- of its earnings as a dividend. Embecta pays out 44.06% of its earnings as a dividend. Embecta's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios MLSS or EMBC?

    Milestone Scientific quarterly revenues are $2.5M, which are smaller than Embecta quarterly revenues of $261.9M. Milestone Scientific's net income of -$1.5M is lower than Embecta's net income of --. Notably, Milestone Scientific's price-to-earnings ratio is -- while Embecta's PE ratio is 13.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Scientific is 8.13x versus 0.68x for Embecta. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MLSS
    Milestone Scientific
    8.13x -- $2.5M -$1.5M
    EMBC
    Embecta
    0.68x 13.00x $261.9M --
  • Which has Higher Returns MLSS or GOSS?

    Gossamer Bio has a net margin of -58.13% compared to Milestone Scientific's net margin of -324.93%. Milestone Scientific's return on equity of -61.33% beat Gossamer Bio's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MLSS
    Milestone Scientific
    73.05% -$0.02 $7.2M
    GOSS
    Gossamer Bio
    -- -$0.14 $251.4M
  • What do Analysts Say About MLSS or GOSS?

    Milestone Scientific has a consensus price target of --, signalling upside risk potential of 131%. On the other hand Gossamer Bio has an analysts' consensus of $7.61 which suggests that it could grow by 485.17%. Given that Gossamer Bio has higher upside potential than Milestone Scientific, analysts believe Gossamer Bio is more attractive than Milestone Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    MLSS
    Milestone Scientific
    0 0 0
    GOSS
    Gossamer Bio
    4 2 0
  • Is MLSS or GOSS More Risky?

    Milestone Scientific has a beta of 1.409, which suggesting that the stock is 40.929% more volatile than S&P 500. In comparison Gossamer Bio has a beta of 1.861, suggesting its more volatile than the S&P 500 by 86.09%.

  • Which is a Better Dividend Stock MLSS or GOSS?

    Milestone Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gossamer Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Scientific pays -- of its earnings as a dividend. Gossamer Bio pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MLSS or GOSS?

    Milestone Scientific quarterly revenues are $2.5M, which are smaller than Gossamer Bio quarterly revenues of $9.5M. Milestone Scientific's net income of -$1.5M is higher than Gossamer Bio's net income of -$30.8M. Notably, Milestone Scientific's price-to-earnings ratio is -- while Gossamer Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Scientific is 8.13x versus -- for Gossamer Bio. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MLSS
    Milestone Scientific
    8.13x -- $2.5M -$1.5M
    GOSS
    Gossamer Bio
    -- -- $9.5M -$30.8M
  • Which has Higher Returns MLSS or INGN?

    Inogen has a net margin of -58.13% compared to Milestone Scientific's net margin of -12.18%. Milestone Scientific's return on equity of -61.33% beat Inogen's return on equity of -19.02%.

    Company Gross Margin Earnings Per Share Invested Capital
    MLSS
    Milestone Scientific
    73.05% -$0.02 $7.2M
    INGN
    Inogen
    45.32% -$0.41 $173.9M
  • What do Analysts Say About MLSS or INGN?

    Milestone Scientific has a consensus price target of --, signalling upside risk potential of 131%. On the other hand Inogen has an analysts' consensus of $10.00 which suggests that it could grow by 34.23%. Given that Milestone Scientific has higher upside potential than Inogen, analysts believe Milestone Scientific is more attractive than Inogen.

    Company Buy Ratings Hold Ratings Sell Ratings
    MLSS
    Milestone Scientific
    0 0 0
    INGN
    Inogen
    1 2 0
  • Is MLSS or INGN More Risky?

    Milestone Scientific has a beta of 1.409, which suggesting that the stock is 40.929% more volatile than S&P 500. In comparison Inogen has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.471%.

  • Which is a Better Dividend Stock MLSS or INGN?

    Milestone Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Scientific pays -- of its earnings as a dividend. Inogen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MLSS or INGN?

    Milestone Scientific quarterly revenues are $2.5M, which are smaller than Inogen quarterly revenues of $80.1M. Milestone Scientific's net income of -$1.5M is higher than Inogen's net income of -$9.8M. Notably, Milestone Scientific's price-to-earnings ratio is -- while Inogen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Scientific is 8.13x versus 0.52x for Inogen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MLSS
    Milestone Scientific
    8.13x -- $2.5M -$1.5M
    INGN
    Inogen
    0.52x -- $80.1M -$9.8M
  • Which has Higher Returns MLSS or LUCD?

    Lucid Diagnostics has a net margin of -58.13% compared to Milestone Scientific's net margin of -1055.55%. Milestone Scientific's return on equity of -61.33% beat Lucid Diagnostics's return on equity of -650.37%.

    Company Gross Margin Earnings Per Share Invested Capital
    MLSS
    Milestone Scientific
    73.05% -$0.02 $7.2M
    LUCD
    Lucid Diagnostics
    -43.69% -$0.25 $16.5M
  • What do Analysts Say About MLSS or LUCD?

    Milestone Scientific has a consensus price target of --, signalling upside risk potential of 131%. On the other hand Lucid Diagnostics has an analysts' consensus of $3.50 which suggests that it could grow by 173.44%. Given that Lucid Diagnostics has higher upside potential than Milestone Scientific, analysts believe Lucid Diagnostics is more attractive than Milestone Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    MLSS
    Milestone Scientific
    0 0 0
    LUCD
    Lucid Diagnostics
    4 0 0
  • Is MLSS or LUCD More Risky?

    Milestone Scientific has a beta of 1.409, which suggesting that the stock is 40.929% more volatile than S&P 500. In comparison Lucid Diagnostics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock MLSS or LUCD?

    Milestone Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lucid Diagnostics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Scientific pays -- of its earnings as a dividend. Lucid Diagnostics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MLSS or LUCD?

    Milestone Scientific quarterly revenues are $2.5M, which are larger than Lucid Diagnostics quarterly revenues of $1.2M. Milestone Scientific's net income of -$1.5M is higher than Lucid Diagnostics's net income of -$12.4M. Notably, Milestone Scientific's price-to-earnings ratio is -- while Lucid Diagnostics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Scientific is 8.13x versus 14.20x for Lucid Diagnostics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MLSS
    Milestone Scientific
    8.13x -- $2.5M -$1.5M
    LUCD
    Lucid Diagnostics
    14.20x -- $1.2M -$12.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

3 Safest Stocks to Buy Now
3 Safest Stocks to Buy Now

With the S&P 500 now in correction and stocks selling…

Tesla Stock: The Bear Case
Tesla Stock: The Bear Case

The recent stock market drop has been a punishing time…

Stock Ideas

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Sell
47
Is MSFT Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 32x

Alerts

Sell
5
CABO alert for Mar 14

Cable One [CABO] is down 3.97% over the past day.

Sell
38
ADBE alert for Mar 14

Adobe [ADBE] is up 4.43% over the past day.

Sell
29
CAR alert for Mar 14

Avis Budget Group [CAR] is up 11.68% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock